insights_auto
Why is 6160 down 2.35%?
Dive Deeperchevron_right
6160:HKG
BeOne Medicines AG
HK$249.80
arrow_downward
-2.35%(-6.00) 1D
Nov 13, 4:08:15 PM GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 6160...
Open
HK$249.40
High
HK$252.00
Low
HK$248.20
Mkt. cap
394.53B
Avg. vol.
3.44M
Volume
2.40M
P/E ratio
52.63
52-wk high
HK$267.00
52-wk low
HK$153.00
EPS
HK$4.75
Shares outstanding
1.43B
No. of employees
12K
Open
HK$249.40
High
HK$252.00
Low
HK$248.20
Mkt. cap
394.53B
Avg. vol.
3.44M
Volume
2.40M
P/E ratio
52.63
52-wk high
HK$267.00
52-wk low
HK$153.00
EPS
HK$4.75
Shares outstanding
1.43B
No. of employees
12K
News stories
From web sources and news partners
qz.com
·
10 minutes ago
How much of the S&P 500 is Nvidia? Concentration explained
Investing.com
·
19 minutes ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.10%
TradingView
·
50 minutes ago
SA analyst says patience will reward the bulls
Yahoo Finance
·
1 hour ago
Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitebeonemedicines.com